Walter H. Moos, Ph.D., is a managing director of Pandect Bioventures. He retired as President of SRI Biosciences in early 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). Prior to SRI he served as Chairman and CEO of MitoKor (Migenix), and as a Vice President at Chiron (Novartis) and Warner-Lambert / Parke-Davis (Pfizer). His teams have advanced numerous pharmaceutical products from discovery to commercialization. He has served on about 20 business and scientific boards, including Amunix, Oncologic (Aduro), Onyx (Amgen), Rigel and the Biotechnology Industry Organization (BIO).

Walter holds Ph.D. and A.B. degrees in chemistry from UC Berkeley and Harvard, respectively.